PROTECT AKTIENANLEIHE - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 14:04:30 2024-05-17 EDT | ||
| 99.98 EUR | 0.00% |
|
| Current month | +0.01% | ||
| 1 month | -0.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 99.98 | 0.00% |
| 24-05-16 | 99.98 | -0.02% |
| 24-05-15 | 100 | +0.01% |
| 24-05-14 | 99.99 | +0.01% |
| 24-05-13 | 99.98 | +0.04% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 02:04 pm
More quotesStatic data
| Product type | Aktienanleihen |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VU8P4P |
| ISIN | DE000VU8P4P3 |
| Date issued | 2023-07-10 |
| Strike | 530.9 kr |
| Maturity | 2024-06-21 (35 Days) |
| Parity | 0.53 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.3 € |
|---|---|
| Lowest since issue | 96.69 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- Certificat
